DLBCL Drug Pipeline: CAR-T, Bispecific & ADC — PatSnap Eureka
DLBCL Drug Pipeline: CAR-T, Bispecific Antibodies & ADC Approaches
Diffuse Large B-Cell Lymphoma accounts for approximately 31% of adult NHL cases in Western countries. With 35–40% of patients relapsing after R-CHOP, patent intelligence reveals three converging therapeutic modalities reshaping the R/R DLBCL landscape.
DLBCL: Molecular Subtypes and Key Therapeutic Targets
DLBCL is a clinically and biologically heterogeneous disease stratified by cell-of-origin (COO) into two major molecular subtypes: activated B-cell (ABC) and germinal center B-cell (GCB). Multiple patent filings from F. Hoffmann-La Roche AG describe DNA-based methods to classify DLBCL COO, indicating that the ABC subtype carries a poorer prognosis and distinct treatment vulnerabilities compared to GCB.
The five-year survival rate ranges from 55–62%, with relapsed/refractory (R/R) patients facing severely limited options. PatSnap's life sciences intelligence platform tracks the full IP landscape across these therapeutic modalities, enabling R&D teams to identify white space and competitive positioning.
Key surface antigens and signaling nodes targeted across the retrieved dataset include CD19 (dominant CAR-T target), CD20 (established rituximab target), CD79b (ADC target for polatuzumab vedotin), and the BCR/BTK/NF-κB pathway — a validated hallmark of ABC-DLBCL. According to the National Cancer Institute, DLBCL remains the most common aggressive lymphoma globally, underscoring the urgency of pipeline innovation.
Academic literature highlights that NF-κB activation via chronic BCR signaling or constitutive MYD88 signaling is a hallmark of ABC-DLBCL, with MALT1 identified as a downstream therapeutic node. Prognostic markers such as CD5 and CD43 co-expression are associated with inferior event-free survival in 200-patient DLBCL cohorts.
Three Converging Approaches Reshaping DLBCL Treatment
Patent intelligence from PatSnap analytics reveals distinct IP landscapes for CAR-T consolidation, bispecific antibodies, and ADCs — each with unique target profiles and combination strategies.
CAR-T Cell Therapy (Anti-CD19)
CAR-T cell therapy targeting CD19 is the most prominently featured cellular immunotherapy in the retrieved dataset. Juno Therapeutics (now a Bristol-Myers Squibb company) details adoptive cell therapy methods using anti-CD19 CAR-T cells administered as a single dose (1×10⁸ total CAR-expressing T cells at dose level DL2) for patients with DLBCL, high-grade B-cell lymphoma, and transformed follicular lymphoma. Approximately 90% of the treated patient cohort had at least one high-risk disease feature.
140 patients underwent leukapheresis in Juno cohortT-Cell Engagers & Checkpoint Bispecifics
Bispecific antibody approaches fall into two subcategories: T-cell engagers (redirecting CD3+ T cells to tumor antigens) and checkpoint/co-stimulatory bispecifics. Amgen covers blinatumomab (CD19×CD3 BiTE) plus pembrolizumab with PD-L1 expression as a stratification criterion. Roche describes a CD20 T-cell bispecific (CD20-TCB) combined with a PD1-LAG3 bispecific, showing statistically significant tumor regression in preclinical models.
5+ organizations with active PD-L1×CD137 patentsAnti-CD79b ADC (Polatuzumab Vedotin)
The most DLBCL-specific ADC evidence centers on anti-CD79b immunoconjugates, specifically polatuzumab vedotin (anti-CD79b–MMAE). Multiple Genentech filings across JP, TW, and CN jurisdictions claim methods for treating DLBCL using anti-CD79b immunoconjugates in combination with immunomodulatory agents (lenalidomide), anti-CD20 antibodies, and standard chemotherapy. Approximately half of relapsed DLBCL patients fail second-line therapy.
Genentech: dominant IP estate across JP, TW, CNBTK Inhibitors, PI3K Inhibitors & IMiDs
Several retrieved patents address small molecule interventions particularly for the ABC subtype. Janssen Pharma filings describe BTK inhibitors for DLBCL with CCL3 and CCL4 as pharmacodynamic biomarkers. Bayer Pharma filings detail copanlisib (a pan-PI3K inhibitor) biomarkers including BCR pathway genes and PI3K pathway genes for DLBCL stratification. Celgene (now BMS) holds multiple IL-jurisdiction patents for lenalidomide in DLBCL.
ABC-DLBCL: primary subtype for BTK/PI3K targetingKey Metrics from the DLBCL Patent Dataset
Visualizing assignee activity and molecular target distribution across CAR-T, bispecific, and ADC modalities as identified through PatSnap Eureka patent analysis.
DLBCL Patent Assignee Activity by Filing Count
Roche/Genentech leads the DLBCL patent landscape with the broadest multi-modality IP estate spanning ADC, bispecific, and COO subtyping filings.
Patent Filing Share by Therapeutic Modality
ADC and CAR-T filings collectively represent the majority of DLBCL-specific patent activity, with bispecifics showing rapid growth across multiple assignees.
Six Emerging Combination Strategies in DLBCL
Retrieved patent filings signal converging multi-modality strategies designed to address the limitations of single-agent approaches in relapsed/refractory DLBCL.
Anti-CD79b ADC + Anti-CD20 + Lenalidomide
Multiple Genentech patents filed across JP, TW, and CN describe this triple-modality approach as the most extensively claimed combination for DLBCL. Polatuzumab vedotin combined with obinutuzumab/rituximab and lenalidomide signals intent to address both direct cytotoxicity and immune modulation simultaneously.
CAR-T + BTK Inhibition
The University of Pennsylvania filing covers CD19-CAR-T combined with BTK inhibitors, rationalizing that BTK inhibition may improve the tumor microenvironment for CAR-T engraftment or reduce antigen-driven T-cell exhaustion. This represents preclinical-stage evidence in the retrieved data.
CD20-TCB + Dual Checkpoint Bispecific (PD1-LAG3)
The Roche 2023 IL filing represents an emerging direction combining a T-cell redirecting bispecific (CD20-TCB) with a simultaneous dual checkpoint blockade bispecific — potentially offering complementary mechanisms of tumor-antigen-driven T-cell redirection plus relief of LAG3-mediated and PD1-mediated T-cell exhaustion.
CAR-T Response Prediction via TME Profiling
BostonGene's WO patent signals an emerging companion diagnostic direction — stratifying DLBCL patients by lymphoma microenvironment (LME) type prior to CAR-T administration, which could improve patient selection and reduce non-response rates.
Key Targets & Patent Evidence Across the DLBCL Pipeline
Each target is supported by specific patent filings identified through PatSnap's innovation intelligence platform. The European Bioinformatics Institute maintains reference data on these B-cell surface antigens and signaling nodes.
| Target | Modality | Key Assignee(s) | Clinical Signal | Subtype Relevance |
|---|---|---|---|---|
| CD19 | CAR-T Cell Therapy | Juno Therapeutics (BMS), Univ. of Pennsylvania | Clinical-stage; 140 patients leukapheresed in Juno cohort | All DLBCL subtypes |
| CD79b | ADC (polatuzumab vedotin) | Genentech, Inc. (JP, TW, CN, WO) | Regulatory approval referenced in Genentech CN patent text | All DLBCL subtypes; R/R setting |
| CD20 | Antibody / T-cell bispecific | F. Hoffmann-La Roche AG, Roche Diagnostics | Established target; biomarker-guided response prediction patents | All DLBCL subtypes |
| BTK / BCR axis | Small molecule inhibitor | Janssen Pharma, Pharmacyclics | CCL3/CCL4 biomarker-guided patient selection | ABC-DLBCL (primary) |
| PI3K pathway | Small molecule (copanlisib) | Bayer Pharma AG | Biomarker panel: PIK3CD, AKT, PTEN, BTK, SYK | ABC-DLBCL / BCR-upregulated |
| PD-L1 / PD-1 | Checkpoint bispecific / combo | Amgen Inc., F. Hoffmann-La Roche AG | PD-L1 expression in 140-patient DLBCL cohort; IND-stage blinatumomab+pembro | All subtypes; immune evasion |
Identify freedom-to-operate gaps in DLBCL targets
PatSnap Eureka maps CDR sequences, jurisdiction coverage, and expiry dates across the full anti-CD79b and anti-CD19 IP estates.
What the DLBCL Patent Landscape Means for R&D Strategy
Derived from analysis of patent filings and academic literature via PatSnap Eureka. See also how life sciences teams use PatSnap for competitive intelligence.
CD79b as the Anchor ADC Target in DLBCL
Retrieved results consistently position anti-CD79b as the dominant ADC target in DLBCL, with Genentech holding a strong IP estate across multiple jurisdictions. New entrants into DLBCL ADC development will need to differentiate by linker-payload technology, novel epitopes, or combination strategies to avoid freedom-to-operate issues.
Genentech IP spans JP, TW, CN, WO jurisdictionsCAR-T Consolidation Is IP-Intensive & Clinically Advancing
The Juno Therapeutics filing documents patient-level manufacturing data, indicating active clinical translation. TME-based response prediction tools (BostonGene) represent an emerging companion diagnostic opportunity that could differentiate patient selection for CAR-T consolidation and reduce treatment failures.
BostonGene WO patent: TME-based CAR-T response predictionBispecific Space Is Crowded but Mechanistically Diversifying
Retrieved results include at least five distinct organizations (MacroGenics, MSD/Merck, Genmab, ABL Bio, BioNTech) with active patents on PD-L1×CD137 or related bispecific formats. The field is moving toward conditional co-stimulation (tumor-antigen-dependent CD137 agonism) to improve safety over unconditional 4-1BB agonists.
5+ orgs with PD-L1×CD137 bispecific patentsABC-DLBCL Subtype Remains an Underserved Niche
Multiple retrieved results highlight inferior outcomes in ABC-DLBCL versus GCB-DLBCL with R-CHOP. The BCR/BTK/NF-κB pathway is a validated but incompletely exploited target in this subtype, with emerging combination opportunities including BTK inhibitor + CAR-T and BTK inhibitor + PI3K inhibition.
ABC-DLBCL: poorer prognosis vs. GCB with R-CHOPFrom Patent Filing to Clinical Evidence
Among retrieved results, the anti-CD19 CAR-T Juno Therapeutics CN patent references a patient cohort in which 140 subjects had undergone leukapheresis, with specific dropout and manufacturing failure rates documented — language consistent with prospective interventional trial reporting.
The Genentech CN patent explicitly references CAR-T and polatuzumab vedotin-piiq + bendamustine + rituximab as recently approved treatments for R/R DLBCL, confirming regulatory approval status as documented within the retrieved patent text. The same filing describes treatment outcomes in terms of hazard ratios and complete response rates across treated patient populations.
Amgen's filings describe specific clinical endpoints (complete response thresholds, disease progression timing) for the blinatumomab + pembrolizumab combination in DLBCL, suggesting at least IND-stage or clinical study design formalization. According to ClinicalTrials.gov, multiple DLBCL combination trials are actively recruiting, reflecting the pipeline activity visible in these patent filings.
Roche's 2023 IL filing describes in vivo tumor regression experiments comparing CD20-TCB + PD1-LAG3 bispecific to nivolumab-based regimens, with statistical significance analysis — consistent with late-stage preclinical or IND-enabling work. PatSnap's data trust center provides full transparency on how patent data is sourced and validated for life sciences intelligence.
DLBCL Drug Pipeline — Key Questions Answered
Approximately 35–40% of patients relapse or are refractory after first-line R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), creating urgent demand for novel therapeutic strategies.
DLBCL is stratified by cell-of-origin (COO) into two major molecular subtypes: activated B-cell (ABC) and germinal center B-cell (GCB). The ABC subtype carries a poorer prognosis and distinct treatment vulnerabilities compared to GCB.
CD19 is the dominant antigen for CAR-T therapies in retrieved results. Anti-CD19 CAR-T cells with 4-1BB or CD28 co-stimulatory domains form the backbone of adoptive therapy in B-cell malignancies including DLBCL.
CD79b is a B-cell receptor–associated signaling subunit and the target of the ADC polatuzumab vedotin. Retrieved results suggest CD79b is the most patent-protected ADC target in DLBCL specifically, with Genentech holding a strong IP estate across multiple jurisdictions.
Retrieved results signal several converging combination strategies including: anti-CD79b ADC + anti-CD20 + lenalidomide; CAR-T + BTK inhibition; CD20-TCB + dual checkpoint bispecific (PD1-LAG3); and TIGIT blockade + anti-PD1 + anti-CD20 for DLBCL.
BTK biomarker data from Janssen and Pharmacyclics filings confirm CCL3 (>40 pg/mL) and CCL4 (>180 pg/mL) as serum indicators of BCR pathway activity and predictors of BTK inhibitor sensitivity in ABC-DLBCL.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About DLBCLAccelerate Your DLBCL Drug Discovery Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — from CAR-T IP landscaping to ADC freedom-to-operate analysis.
References
- Methods for articles and products for adoptive cell therapy — Juno Therapeutics (Bristol-Myers Squibb subsidiary), 2024, CN [Patent]
- Tumor microenvironment-based methods for assessing CAR-T and other immunotherapies — BostonGene Corporation, 2022, WO [Patent]
- Combination of chimeric antigen receptor therapy and aminopyrimidine derivatives — The Trustees of the University of Pennsylvania, 2021, ES [Patent]
- Compositions and methods for treating diffuse large B cell lymphoma — Amgen Inc., 2020, IL [Patent]
- Compositions and methods for treating diffuse large B cell lymphoma (second filing) — Amgen Inc., 2020, IL [Patent]
- Combination therapy employing a PD1-LAG3 bispecific antibody and a CD20 T cell bispecific antibody — F. Hoffmann-La Roche AG, 2023, IL [Patent]
- Multispecific binding agents against PD-L1 and CD137 in combination with anti-PD-1 antibodies for treating cancers — MSD International Business GmbH, 2024, IL [Patent]
- Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof — MacroGenics, Inc., 2019, SG [Patent]
- Methods of using anti-CD79b immunoconjugates to treat diffuse large B-cell lymphoma — Genentech, Inc., 2023, TW [Patent]
- Methods of using anti-CD79b immunoconjugates to treat diffuse large B-cell lymphoma (Japanese filing) — Genentech, Inc., 2024, JP [Patent]
- Using anti-CD79b immunoconjugates to treat diffuse large B-cell lymphoma — Genentech, Inc., 2024, CN [Patent]
- Methods of using anti-CD79b immunoconjugates to treat DLBCL: combination with anti-CD20 antibodies, chemotherapy and corticosteroids — F. Hoffmann-La Roche AG, 2024, JP [Patent]
- HDAC inhibitors-based antibody drug conjugates (ADCs) and use in therapy — Alfasigma S.p.A., 2019, SG/WO [Patent]
- Prediction and characterization of DLBCL cell of origin subtypes — F. Hoffmann-La Roche AG, 2020, WO [Patent]
- Prediction and characterization of DLBCL cell of origin subtypes (second filing) — F. Hoffmann-La Roche AG, 2020, WO [Patent]
- Predicting response to anti-CD20 therapy in DLBCL patients — Roche Diagnostics GmbH, 2014, EP [Patent]
- Predicting response to anti-CD20 therapy in DLBCL patients (WO filing) — F. Hoffmann-La Roche AG, 2013, WO [Patent]
- National Cancer Institute — Lymphoma Information — NCI, cancer.gov
- ClinicalTrials.gov — DLBCL Active Clinical Trials — U.S. National Library of Medicine
- European Bioinformatics Institute — B-cell antigen reference data — EMBL-EBI
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.